Suraksha Diagnostic Limited — PPTs, 21-12-2024: Investor Presentation

Suraksha Diagnostic Limited has revised its Investor Presentation, reflecting updates on financial results for the quarter and half-year. The key changes in Slide 6 include the adjustment of figures for the Kolkata and Hooghly centres in their operational mapping. This update is available on the company's website and will be presented to analysts and investors during upcoming meetings.

### Financial Highlights

For H1 FY25, total income reached ₹1,299 Mn, up 15% YoY, with EBITDA increasing by 25% to ₹462 Mn. The PAT surged 45% to ₹178 Mn, showcasing significant growth in profitability.

### Strategic Initiatives and Growth Drivers

The company aims to expand its diagnostic centres and enhance medical consultations while leveraging technology for improved customer experience. Strategic partnerships and selective acquisitions are also in focus to drive growth in Eastern and North-Eastern India.

### Business Developments

Suraksha operates 51 diagnostic centres and 178 collection centres, serving 0.61 Mn patients with an average of ₹2,099 in revenue per patient during H1 FY25.

### Market Position and Competitive Advantage

As the largest diagnostic chain in Eastern India, Suraksha is well-positioned in a fragmented market with low penetration, targeting substantial market opportunities with a robust operational framework.

### Investor Implications

The strong financial performance and strategic growth initiatives suggest a positive outlook for Suraksha, presenting potential growth opportunities for investors. The strong market positioning and expansion plans could enhance shareholder value moving forward.